Clinical trial
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve…
NCT00266643 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00266643 |
|---|---|
| Title | Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain |
| Official title | A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy, Painful |
| Intervention type | Drug |
| Interventions | duloxetine hydrochloride |
| Enrollment | 205 |
| Start date | Dec 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Dec 19, 2005 |
| Last update posted | Aug 3, 2007 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: